Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections.
about
Antibiotic therapy for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) in non surgical woundsTedizolid phosphate (sivextro): a second-generation oxazolidinone to treat acute bacterial skin and skin structure infectionsNew Is Old, and Old Is New: Recent Advances in Antibiotic-Based, Antibiotic-Free and Ethnomedical Treatments against Methicillin-Resistant Staphylococcus aureus Wound InfectionsPotential role of tedizolid phosphate in the treatment of acute bacterial skin infectionsNew developments in the management of severe skin and deep skin structure infections - focus on tedizolidPlatelet profile in patients with acute bacterial skin and skin structure infections receiving tedizolid or linezolid: findings from the Phase 3 ESTABLISH clinical trials.Tedizolid Phosphate: a Next-Generation Oxazolidinone.Pharmacokinetic drug evaluation of tedizolid for the treatment of skin infections.In vitro and in vivo activities of three oxazolidinones against nonreplicating Mycobacterium tuberculosis.A mouse model to evaluate the impact of species, sex, and lipid load on lymphatic drug transportNewer antibacterials in therapy and clinical trialsPharmacokinetics of tedizolid following oral administration: single and multiple dose, effect of food, and comparison of two solid forms of the prodrugTedizolid population pharmacokinetics, exposure response, and target attainment.Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment.Tedizolid phosphate.Skin and soft tissue concentrations of tedizolid (formerly torezolid), a novel oxazolidinone, following a single oral dose in healthy volunteersSingle- and multiple-dose pharmacokinetics and absolute bioavailability of tedizolidLack of neuropathological changes in rats administered tedizolid phosphate for nine months.Impact of granulocytes on the antimicrobial effect of tedizolid in a mouse thigh infection modelProfile of tedizolid phosphate and its potential in the treatment of acute bacterial skin and skin structure infectionsComparative in vivo efficacies of epithelial lining fluid exposures of tedizolid, linezolid, and vancomycin for methicillin-resistant Staphylococcus aureus in a mouse pneumonia model.Pulmonary disposition of tedizolid following administration of once-daily oral 200-milligram tedizolid phosphate in healthy adult volunteers.Pharmacokinetics and pulmonary disposition of tedizolid and linezolid in a murine pneumonia model under variable conditions.Comparative efficacies of human simulated exposures of tedizolid and linezolid against Staphylococcus aureus in the murine thigh infection model.In vitro activity and microbiological efficacy of tedizolid (TR-700) against Gram-positive clinical isolates from a phase 2 study of oral tedizolid phosphate (TR-701) in patients with complicated skin and skin structure infections.Comparative pharmacodynamics of the new oxazolidinone tedizolid phosphate and linezolid in a neutropenic murine Staphylococcus aureus pneumonia modelIn vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions.Advances in MRSA drug discovery: where are we and where do we need to be?The rationality for using prodrug approach in drug discovery programs for new xenobiotics: opportunities and challenges.The oxazolidinones: past, present, and future.Tedizolid (TR-701): a new oxazolidinone with enhanced potency.Prospects for new antibiotics: a molecule-centered perspective.Recent advances in antibacterial drugs.Current strategies for the treatment of complicated intraabdominal infections.Use of pharmacokinetic/pharmacodynamic systems analyses to inform dose selection of tedizolid phosphate.Early experience with tedizolid: clinical efficacy, pharmacodynamics, and resistance.The times they are a-changin': new antibacterials for skin and skin structure infections.Pharmacokinetics of ertapenem in colorectal tissue.Tedizolid: The First Once-Daily Oxazolidinone Class Antibiotic.Tedizolid for treatment of acute bacterial skin and skin structure infections.
P2860
Q24202424-2921DFBC-EF89-4338-8270-2236F0212817Q24561509-AE13EB6D-F839-4257-81DD-245EB5087B44Q26749376-7C80CE5B-8FC0-4EB4-B693-91ACF863582DQ26853612-EA13C406-8F2E-4A14-88C0-3B870454B789Q28083116-9AF80520-8BBA-4187-B00E-91E8A97F1D3AQ33417790-06F0937A-35B1-45C9-81AE-FAF4784CDB70Q33420646-9401A946-5EEA-4B86-B69F-B6A0601F6DEDQ33438834-1A27F00E-CA69-465D-9553-606E09852EBBQ33798173-3F37C9F7-740E-4025-B1EE-F678DEF8624BQ34060125-6E26C89B-EFAC-4D0D-96A9-29B282D51D92Q34488329-66B2FEE2-B14A-4315-9E2C-A8BE4D9E15C7Q34548251-56A91796-BFBE-4199-AE95-9D1F10D050B2Q34596353-79E1C11C-7CFA-41DC-BFCD-381D0B24018BQ34596658-924CC1DE-A30A-4919-B508-C0A0AFDC0118Q34612944-61FD0394-3BB7-4C2C-86C9-38E899BD617EQ34638260-2C75B767-9300-4010-8F23-2B802A5E4565Q34658779-B41C3A1F-0B4F-44FD-8C99-092D72CAE3B9Q34922770-06711241-252D-4D79-A89E-4B03C1BD1DA0Q35364245-FF892BF8-A380-4C4F-AF1F-8902BB5700C2Q35542330-B6387D0A-8DD9-43B5-9E78-A48C68208A5DQ35941253-1E6288B2-42FD-4EDF-B590-DD0E9F7CD4F1Q35941279-CCF3D5FD-B4D5-4C5D-8128-93CB5813D71CQ36018731-A608FCA5-6E3E-4537-BD47-3172F4CE6097Q36171683-02C9A332-4DDC-4EA0-A46E-F025308519B1Q36172450-F35D0BA1-9B35-4237-AA8D-D7C7EF70288DQ36364009-730E2DBC-571C-4484-B503-2F6E7A0D0467Q36969769-6E732805-74FE-4A77-B73C-D94149A356A9Q37112508-207F4474-8432-4677-85A8-F16FE30691C2Q37853071-DDB2C70F-DEC6-4D25-ADC2-CF52F48EA6E2Q37970719-CDCF3F64-5E7E-4F91-8CC4-1572D2B77ADCQ37983130-1F6C8A43-6F46-4F46-BECC-33BD3F88B212Q38113689-FEEC0F16-218B-4175-A1B6-B385F2F02054Q38115306-3FD50853-C689-4D1C-A279-413EF7E4A09DQ38123247-35845ADC-1A1C-44FA-9EB5-72D21ECC8E91Q38171760-0F91426B-1DB1-4463-97BB-2702A38AC8C3Q38255366-D136167F-9FEF-44EE-A98F-95F081913F10Q38438503-29E20663-F489-411C-A80F-DB0CC1E139ECQ38479091-89E92657-D5A2-46C1-807F-3D9F2158C801Q38536296-BC214ED4-BE98-4E73-964F-0EE9BC58A6A3Q38554583-6C85285F-1175-442D-BAF0-905245ACFEB7
P2860
Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections.
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Phase 2, randomized, double-bl ...... and skin structure infections.
@ast
Phase 2, randomized, double-bl ...... and skin structure infections.
@en
Phase 2, randomized, double-bl ...... and skin structure infections.
@nl
type
label
Phase 2, randomized, double-bl ...... and skin structure infections.
@ast
Phase 2, randomized, double-bl ...... and skin structure infections.
@en
Phase 2, randomized, double-bl ...... and skin structure infections.
@nl
prefLabel
Phase 2, randomized, double-bl ...... and skin structure infections.
@ast
Phase 2, randomized, double-bl ...... and skin structure infections.
@en
Phase 2, randomized, double-bl ...... and skin structure infections.
@nl
P2093
P2860
P356
P1476
Phase 2, randomized, double-bl ...... and skin structure infections
@en
P2093
P2860
P304
P356
10.1128/AAC.00076-10
P407
P577
2010-11-29T00:00:00Z